Here is the complete video.
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
There are looking for synergies and trying to use the unutilised capacity.
Syngene do have some unutilised capacity in Mangalore and Bangalore(Strides).
I don’t track Biocon but know that their business is of biosimilars(biologics generics) and they can’t setup new capacity for some time due to huge debt if they don’t have much now.
Neither they can sell more of Syngene to reduce debt as they will lose majority stakes in Syngene.
It is not a succession planning as confirmed by Kiran Shaw in the video.
Also it was said that the individual CEO will have the autonomy but later a contradicting statement was said as synergies across the group is above the individual company growth prospect.
The only thing that can make my point invalid is that if Biocon has unutilised capacity for small molecule as well large molecule.
Disclosure : I can be terribly wrong. I am comparatively new to the market. Syngene is part of my high conviction bet.
Subscribe To Our Free Newsletter |